医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Waters UPLC I-Class/Xevo TQ-S System Approved for In Vitro Diagnostic Use in China

2015年04月14日 PM09:35
このエントリーをはてなブックマークに追加


 

MILFORD, Mass.

Waters Corporation (NYSE: WAT) today announced that the Chinese Food and Drug Administration (CFDA) approved the Waters® ACQUITY UPLC® I- Class IVD/Xevo® TQ-S IVD System for in vitro diagnostic (IVD) use in China. The system was approved for clinical analysis of a variety of compounds that include diagnostic indicators and compounds for treatment monitoring.

“The practice of medicine is changing from a reactive approach to treating disease, to one that is more proactive and preventive,” said Jeff Mazzeo, Senior Director, Health Sciences for Waters Division. “To facilitate this transition, better diagnostic and predictive tools are needed so that disease can be detected earlier or even prevented. That is where Waters technologies like the ACQUITY® TQD System and ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD systems, approved for IVD use by the CFDA in 2014 and 2015, respectively, can make a significant impact.”

Using LC-MS technology, clinical laboratories perform qualitative and quantitative analyses of patients’ samples to aid clinicians in many ways. These tests may be used to confirm a clinical suspicion (including making a diagnosis); assist in the selection, optimization and monitoring of treatment; provide a prognosis; screen for disease in the absence of clinical signs or symptoms; and establish and monitor the severity of physiological disturbance. Liquid chromatography separates analytes and interferents within a given sample, while mass spectrometry technology is used for detection and confirmation of those analytes.

The recently CFDA approved ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD System features Waters’ UltraPerformance LC® technology coupled with a tandem quadrupole mass spectrometer designed for the most demanding UPLC-MS/MS quantitative analysis. This system uses StepWave™, a breakthrough off-axis ion source technology, and RADAR™, an information rich acquisition method, enabling the system with sensitivity and robustness.

For more information, please visit Waters’ Clinical application page.

About Waters Corporation (www.waters.com)

For over 50 years, Waters Corporation (NYSE: WAT) has been enabling significant progress in the fields of healthcare, environmental management, food safety, and global water quality monitoring by providing practical and sustainable innovations, thus creating business advantages for laboratory-associated organizations.

As a pioneer in separation science, laboratory information management, mass spectrometry, and thermal analysis technology, Waters has created a sustainable platform with its technical breakthroughs and laboratory solutions for the success of its clients.

Waters achieved revenues of $ 1.99 billion in 2014, and it will continue to lead its clients to explore science and achieve excellence.

Waters, ACQUITY, ACQUITY UPLC, UPLC, XEVO, StepWave and RADAR are trademarks of Waters Corporation.

CONTACT

Waters Corporation
Jeff Tarmy, 508-482-2268
jeff_tarmy@waters.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結